Loading stock data…
OBIO
$3.97-0.02 (-0.50%)
Market ClosedLast close May 1
Orchestra BioMed Holdings, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Orchestra BioMed Holdings, Inc. in the Healthcare sector is trading at $3.97. The stock is currently 27% below its 52-week high of $5.42, remaining 5.0% above its 200-day moving average. Technical signals show neutral RSI of 39 and bearish MACD signal, explaining why OBIO maintains its current momentum and trend strength. The Whystock Score of 85/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 39) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$3.97
Potential Upside
5%
Whystock Fair Value$4.17
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, a...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$242.86M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.60
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-98.38%
Volume
Today's trading volume
158,416
Recent News
NovoCure (NVCR) Reports Q1 Loss, Beats Revenue Estimates
NovoCure (NVCR) delivered earnings and revenue surprises of -55.00% and +3.65%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Orchestra BioMed Holdings, Inc. (OBIO) Surpasses Q4 Earnings and Revenue Estimates
Orchestra BioMed Holdings, Inc. (OBIO) delivered earnings and revenue surprises of +168.87% and +3,813.54%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Codexis (CDXS) Beats Q4 Earnings and Revenue Estimates
Codexis (CDXS) delivered earnings and revenue surprises of +2,100.00% and +1.61%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Orchestra BioMed Holdings, Inc.'s (NASDAQ:OBIO) largest shareholders are retail investors with 41% ownership, institutions own 17%
Key Insights Orchestra BioMed Holdings' significant retail investors ownership suggests that the key decisions are...
TD Cowen Initiates Orchestra BioMed (OBIO), Cites High-Margin Potential in Lead Cardiovascular Programs
Orchestra BioMed Holdings Inc. (NASDAQ:OBIO) is one of the best biotech penny stocks to buy according to analysts. On December 10, TD Cowen analyst Joshua Jennings initiated coverage of Orchestra BioMed with a Buy rating and $15 price target. TD Cowen believes that Orchestra BioMed is at the leading edge of cardiovascular device innovation. Its […]